This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

WED Foundation And XenoPort Announce Launch Of New “Patient Odyssey” Survey Assessing Day-to-Day Impact Of RLS/WED On Both Patients And Loved Ones

The Willis-Ekbom Disease (WED) Foundation and XenoPort, Inc. (Nasdaq: XNPT) announced today that they have launched a new “Patient Odyssey” survey, aimed at measuring the challenges of long-term disease management, quality of life (QoL) impact and emotional burden associated with restless legs syndrome/Willis-Ekbom Disease (RLS/WED) among patients, as well as the impact of the disease on relationships with spouses or partners. The survey kicks off during this year’s National RLS/WED Awareness Week, dedicated to the continuation of education that improves diagnosis and treatment of the disease.

“The Foundation looks forward to working with our constituency to dive deeper into the long-term impact of RLS/WED on the patient, including a first-time focus on the impact of the disease from the perspective of spouses and partners,” said Georgianna Bell, executive director of the Willis-Ekbom Disease Foundation. “We hope that the findings of this survey reveal new ways that our organization can provide support to the RLS/WED community, as well as serve as an important educational tool that helps the greater public understand the serious burden of this disease.”

In 2012, the WED Foundation conducted an analysis to examine the patterns, causes and effects of RLS/WED in patients including symptom severity, sleep disturbance and medication dosing for both RLS/WED and comorbid conditions. These findings will be presented at the 2013 World Association of Sleep Medicine (WASM) Congress in Valencia, Spain, from September 28-October 2, 2013. The new “Patient Odyssey” survey is designed to build upon findings from the 2012 survey.

“We are excited to support the WED Foundation on this initiative so that collectively we can better understand the needs of patients with RLS/WED, many of whom have the disease for life and struggle to find optimal disease management plans,” stated Ronald W. Barrett, Ph.D., chief executive officer of XenoPort, Inc. “Our goal with this project is to uncover the patient journey and potentially determine how we can improve the lives of these patients and provide support for their loved ones.”

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs